Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 401–500 of 1,000
Eriksson, B. I., Dahl, O. E., Rosencher, N., Clemens, A., Hantel, S., Feuring, M., Kreuzer, J., Huo, M. H., & Friedman, R. J. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0067-8 · Cited by 26
“7 %) observed in studies with the oral FXa inhibitors (apixaban and rivaroxaban) versus enoxaparin in patients undergoing hip arthroplasty and receiving prophylaxis for an equivalent extended duration [10, 11].”
Self-citationLupi, S. M., & y Baena, A. R. (2020) · Healthcare · doi:10.3390/healthcare8030281 · Cited by 26
Thromboprophylaxis for orthopedic surgery; An updated meta-analysis
Haykal, T., Adam, S. S., Bala, A., Zayed, Y., Deliwala, S. S., Kerbage, J., Ponnapalli, A., Malladi, S., Samji, V., & Ortel, T. L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.007 · Cited by 30
Shargall, Y., Wiercioch, W., Brunelli, A., Murthy, S. C., Hofstetter, W. L., Lin, J., Li, H., Linkins, L., Crowther, M., Davis, R., et al. (2022) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezac488 · Cited by 26
Sarich, T. C., Peters, G. R., Berkowitz, S. D., Misselwitz, F., Nessel, C. C., Burton, P. B. J., Cook‐Bruns, N., Lensing, A. W. A., Haskell, L. P., Perzborn, E., et al. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12136 · Cited by 28
Self-citationRadcliff, K. E., Ong, A., Parvizi, J., Post, Z. D., & Orozco, F. (2014) · Orthopaedic Surgery · doi:10.1111/os.12085 · Cited by 28
Ageno, W., Spyropoulos, A. C., & Turpie, A. G. G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0787 · Cited by 28
“RECORD1 compared rivaroxaban 10 mg od with the LMWH enoxaparin 40 mg od for 31–39 days (28).”
BackgroundNovel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors
Steffel, J., & Lüscher, T. F. (2009) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32832edac0 · Cited by 27
The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?
Renda, G., & Caterina, R. D. (2013) · Vascular Pharmacology · doi:10.1016/j.vph.2013.07.003 · Cited by 28
“Results from the phase III RECORD program [28–31] validated this dose selection for VTE prevention, and 10 mg once daily was approved consequent to the demonstration that rivaroxaban showed non-inferiority and possibly superiority compared with subcutaneous enoxaparin, despite a trend towards increased major bleeding…”
MethodLazo‐Langner, A., Fleet, J. L., McArthur, E., & Garg, A. X. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12675 · Cited by 28
Oswald, E., Velik‐Salchner, C., Innerhofer, P., Tauber, H., Auckenthaler, T., Ulmer, H., & Streif, W. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000203 · Cited by 30
Monréal, M., Folkerts, K., Imberti, D., Brosa, M., & Diamantopoulos, A. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0919 · Cited by 27
“(14) and RECORD2 (10–14 days’ enoxaparin vs 31–39 days’ rivaroxaban) (15) were pooled and used as the source of efficacy and safety data for Italy and Spain.”
The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature
Tahir, F., Riaz, H., Riaz, T., Badshah, M. B., Riaz, I. B., Hamza, A., & Mohiuddin, H. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-18 · Cited by 30
“The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism 1 (RECORD 1) [19] trial compared the efficacy and safety of 10 mg oral rivaroxaban once daily initiated postoperatively to 40 mg subcutaneous enoxaparin once daily initiated preoperatively in the prevention of…”
BackgroundSharma, A., Chatterjee, S., Lichstein, E., & Mukherjee, D. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04874.x · Cited by 26
DeVries, J. H., Kamphuisen, P. W., Kuhls, S., Homering, M., Hoekstra, J. B. L., Lensing, A. W. A., Buller, H. R., Cohn, D. M., & Hermanides, J. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-07-0447 · Cited by 29
“This was performed at day 36 (range 32 to 40) in patients with total hip replacements (RECORD 1 and 2) (11, 12), and at day 13 (range 11 to 15) in patients with total knee replacement (RECORD 3 and 4) (13, 14).”
BackgroundCimminiello, C., Prandoni, P., Agnelli, G., Minno, G. D., Friz, H. P., Scaglione, F., Boracchi, P., Marano, G., & Harenberg, J. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1714-9 · Cited by 28
Thiengwittayaporn, S., Budhiparama, N. C., Tanavalee, C., Tantavisut, S., Sorial, R. M., Cao, L., Kim, K., The Asia-Pacific (AP) Region Venous Thromboembolism (VTE) Consensus Group, Unnanuntana, A., Tan, A., et al. (2021) · Knee Surgery and Related Research · doi:10.1186/s43019-021-00100-8 · Cited by 27
Wang, M., Xie, J., Zheng, H., Wang, S., Zhou, R., Li, W., Xue, E. C., Wang, X., Jiang, J., Wu, T., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15005 · Cited by 25
Mismetti, P., Samama, C. M., Rosencher, N., Vielpeau, C., Nguyên, P., Deygas, B., Presles, É., Laporte, S., & for The PROPICE Study Group (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-09-0640 · Cited by 26
“This bleeding risk is close to that reported in much less fragile patients receiving full prophylactic doses of LMWH or rivaroxaban in the randomised studies (19, 20) and to that observed in clinical practice with full prophylactic doses of LMWH (23) or fondaparinux 2.”
MethodResultSchulman, S., & Majeed, A. (2011) · Drug Safety · doi:10.2165/11587290-000000000-00000 · Cited by 29
“Rivaroxabanwasmore effective than enoxaparin for the prevention of VTE after TKR or THR in four phase III trials (the RECORD [REgulation of Coagulation in ORthopedic surgery to prevent Deep venous thrombosis and pulmonary embolism] programme),([85-88]) regarding the primary outcome (any VTE plus all-cause mortality) a…”
New Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
“(14) In the ADVANCE-3(15) and RECORD-1(16) trials, extended duration apixaban and rivaroxaban were both found to be superior to extended duration LMWH for VTE risk reduction amongst THA patients, with a similar safety profile.”
BackgroundCoulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Management of Anticoagulation Agents in Trauma Patients
McCoy, C. C., Lawson, J. H., & Shapiro, M. L. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.013 · Cited by 25
Transitions of care in anticoagulated patients
Michota, F. A. (2013) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s44068 · Cited by 29
Zindel, S., Stock, S., Müller, D., & Stollenwerk, B. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-192 · Cited by 28
“enoxaparin sodium (40 mg once a day) is initiated on the day before surgery, rivaroxaban (10 mg daily) treatment starts on the day of surgery [4,11,13].”
BackgroundMethodInfluentialThe promise of novel direct oral anticoagulants
Hoffman, R., & Brenner, B. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.06.004 · Cited by 27
“In all the four trials, rivaroxaban was superior to enoxaparin in preventing VTE, with no increase in major bleeding [42–45].”
BackgroundNew Issues in Oral Anticoagulants
Francis, C. W. (2008) · Hematology · doi:10.1182/asheducation-2008.1.259 · Cited by 27
Highcock, A. J., As-Sultany, M., Finley, R., & Donnachie, N. J. (2020) · The Journal of Arthroplasty · doi:10.1016/j.arth.2020.06.032 · Cited by 27
New Antithrombotic Drugs: Potential for Use in Oncology
Levine, M. N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7346 · Cited by 28
Schäfer, S. T., Wiederkehr, T., Kammerer, T., Acevedo, A.-C., Feil, K., Kellert, L., Görlinger, K., Hinske, L. C., & Groene, P. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.019 · Cited by 25
Schäfer, S. T., Otto, A.-C., Acevedo, A.-C., Görlinger, K., Maßberg, S., Kammerer, T., & Groene, P. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00313-7 · Cited by 28
Rivaroxaban for the treatment and prevention of thromboembolic disease
Antoniou, S. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12387 · Cited by 26
Emerging options in the treatment of deep vein thrombosis and pulmonary embolism
Brenner, B., & Hoffman, R. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.04.003 · Cited by 27
“In RECORD1 (patients undergoing THA) rivaroxaban for 31–39 days significantly reduced the rate of the primary efficacy outcomewhen comparedwith enoxaparin 40 mg od for 31–39 days.(49) A similar result was found in RECORD2 (also in patients undergoing THA), which compared rivaroxaban for 31–39 days with enoxaparin 40 m…”
ResultNew Oral Anticoagulants for Thromboprophylaxis After Total Hip or Knee Arthroplasty
Friedman, R. J. (2009) · Orthopedics · doi:10.3928/01477447-20091103-53 · Cited by 24
Self-citationPharmacology and Laboratory Testing of the Oral Xa Inhibitors
Samama, M. M., Meddahi, S., & Samama, C. M. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.009 · Cited by 26
Fusaro, M., Crepaldi, G., Maggi, S., D’Angelo, A., Calò, L. A., Miozzo, D., Fornasieri, A., & Gallieni, M. A. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111797484134 · Cited by 24
“Another novel oral anticoagulant is rivaroxaban: It is a direct Factor Xa inhibitor approved in the EU for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery [66, 67].”
BackgroundMesserschmidt, C. A., & Friedman, R. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303400 · Cited by 27
Self-citationLee, Y., Chung, C. Y., Koo, K., Lee, K. M., Ji, H.-M., & Park, M. S. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.01033 · Cited by 25
Lusk, K. A., Snoga, J. L., Benitez, R. M., & Sarbacker, G. B. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017707126 · Cited by 26
Sun, G., Wu, J., Wang, Q., Liang, Q., Jia, J., Cheng, K., Sun, G., & Wang, Z. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.11.029 · Cited by 27
Revankar, N., Patterson, J., Kadambi, A., Raymond, V., & BSc, W. E.-H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2686 · Cited by 24
The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants
Blann, A. D., & Khoo, C. W. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4621 · Cited by 29
Huo, M. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0653 · Cited by 25
New oral anticoagulants: should they replace heparins and warfarin?
Tsiara, S., Pappas, K. D., Boutsis, D. E., & Laffan, M. (2011) · PubMed · Cited by 24
Fernandez‐Martinez, S., Lenoir, C., Samer, C. F., & Rollason, V. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040250 · Cited by 24
Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture
Gouzoulis, M. J., Joo, P. Y., Kammien, A. J., McLaughlin, W. M., Yoo, B., & Grauer, J. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276548 · Cited by 26
Mehta, R. S. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.5 · Cited by 25
Duggan, S. T. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11208470-000000000-00000 · Cited by 28
“of care anticoagulant, subcutaneous enoxaparin sodium, for the prevention of VTE following THR([45,48]) or TKR([46]) surgery.”
BackgroundInfluentialMarx, S., Dahl, O. E., Marder, V. J., Schulze, A., Wehling, M., Weiß, C., & Harenberg, J. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0482 · Cited by 25
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation
Cabral, K. P., & Ansell, J. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.19 · Cited by 28
A new paradigm shift in antithrombotic therapy
Pudusseri, A., Shameem, R., & Spyropoulos, A. C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00133 · Cited by 25
“The Prasugrel vs. Clopidogrel for ACS without Revascularization (TRILOGY) study was a double-blind, randomized trial to determine the effect of intensified platelet inhibition for patients with unstable angina (USA) or MI without ST-segment elevation without surgical intervention.”
BackgroundInfluentialGinzburg, E., & Dujardin, F. H. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0498-9 · Cited by 27
Surgical trial design – learning curve and surgeon volume
Simpson, H., HOWIE, C. R., & Norrie, J. D. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.64.bjr-2017-0051 · Cited by 23
Kittelson, J. M., Spyropoulos, A. C., Halperin, J. L., Kessler, C. M., Schulman, S., Steg, P. G., Turpie, A. G. G., Cutler, N. R., Hiatt, W. R., & Goldenberg, N. A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12324 · Cited by 23
Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Fonseca, A. G., & D’Cruz, D. P. (2008) · Journal of Autoimmune Diseases · doi:10.1186/1740-2557-5-6 · Cited by 23
Ahmed, A. B., Kozek‐Langenecker, S. A., Mullier, F., Pavord, S. R., & Hermans, C. R. J. R. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000725 · Cited by 28
Rivaroxaban for Thromboprophylaxis
Lippi, G., Franchini, M., & Targher, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmc081524 · Cited by 23
How to prevent, treat, and overcome current clinical challenges of VTE
van Es, J., Eerenberg, E. S., Kamphuisen, P. W., & Buller, H. R. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04334.x · Cited by 24
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713478629 · Cited by 23
Yi, Y.-H., Gong, S., Gong, T.-L., Zhou, L., Hu, C., & Xu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775126 · Cited by 23
“Search Strategy We restricted our analysis to studies that were phase III RCTs and met all of the following inclusion criteria: (1) the population was defined as adult patients (≥18 years) undergoing THA or TKA surgery admitted to and discharged from the hospital; (2) the included study should be an RCT involving one…”
BackgroundMethodInfluentialShargall, Y., Wiercioch, W., Brunelli, A., Murthy, S. C., Hofstetter, W. L., Lin, J., Li, H., Linkins, L., Crowther, M., Davis, R., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.05.041 · Cited by 22
REVIEW: New Antithrombotics for Atrial Fibrillation
Bereznicki, L., & Peterson, G. M. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00209.x · Cited by 24
Kubitza, D., Becka, M., Mück, W. M., & Kraetzschmar, J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12349 · Cited by 22
Nuevos anticoagulantes orales y su papel en la práctica clínica
Mateo, J. (2013) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(13)70057-8 · Cited by 58
Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy
Muñoa, L., González, A. B., de Rada, P. D., Valentí-Azcárate, A., & Valentí, J. R. (2013) · MUSCULOSKELETAL SURGERY · doi:10.1007/s12306-013-0287-7 · Cited by 24
“knee arthroplasty [11, 19, 21, 31].”
BackgroundInfluentialRisk of Gastrointestinal Bleeding with Dabigatran: A Head-to-Head Comparative Study with Rivaroxaban
Sherid, M., Sifuentes, H., Sulaiman, S., Samo, S., Husein, H., Tupper, R. S., Thiruvaiyaru, D. S., Spurr, C., & Sridhar, S. (2014) · Digestion · doi:10.1159/000365967 · Cited by 27
Russell, R. D., Hotchkiss, W. R., Knight, J. R., & Huo, M. H. (2013) · Thrombosis · doi:10.1155/2013/762310 · Cited by 25
“5% in the enoxaparin group, which was not statistically significant [18].”
BackgroundNovel oral anticoagulants for thromboprophylaxis after orthopaedic surgery
Quinlan, D. J., & Eriksson, B. I. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.003 · Cited by 27
Self-citationApixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty: A Meta-Analysis
Alves, C., Marques, F. B., & Macedo, A. F. (2011) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248411427402 · Cited by 28
“Several RCTs compared rivaroxaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty, reporting higher efficacy of rivaroxaban when compared with both European and North American enoxaparin regimens.(23,24,41,42) A previous meta-analysis confirmed that rivaroxaban was superior to enoxaparin…”
ResultMilinis, K., Shalhoub, J., Coupland, A., Salciccioli, J. D., Thapar, A., & Davies, A. H. (2018) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2018.05.020 · Cited by 22
Hamidi, M., Zeeshan, M., Sakran, J. V., Kulvatunyou, N., O’Keeffe, T., Northcutt, A., Zakaria, E. R., Tang, A. L., & Joseph, B. A. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.09.023 · Cited by 27
Vasilakis, V., Kortesis, B. G., Bharti, G., Isakson, M. H., & Hunstad, J. P. (2020) · Aesthetic Surgery Journal · doi:10.1093/asj/sjaa177 · Cited by 22
Gionis, M. N., Ioannou, C. V., Katsamouris, A. N., Katonis, P., Balalis, K., Sfyridaki, K., Elalamy, I., & Gerotziafas, G. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.09.037 · Cited by 22
Boland, M. R., Murphy, M., Murphy, M., & McDermott, E. W. M. (2012) · Journal of Medical Case Reports · doi:10.1186/1752-1947-6-129 · Cited by 23
Wanderling, C. R., Liles, J., Finkler, E. S., Carlsgaard, P., Hopkinson, W. J., Güler, N., Hoppensteadt, D., & Fareed, J. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617700998 · Cited by 22
Direct-Acting Oral Anticoagulants in Critically Ill Patients
Rali, P. M., Gangemi, A. J., Moores, A., Mohrien, K. M., & Moores, L. K. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.025 · Cited by 24
Carrothers, A. D., Rodriguez-Elizalde, S., Rogers, B. A., Razmjou, H., Gollish, J. D., & Murnaghan, J. J. (2014) · The Journal of Arthroplasty · doi:10.1016/j.arth.2013.02.001 · Cited by 24
Rivaroxaban for the treatment of venous thromboembolism in pediatric patients
Cohen, O., Levy‐Mendelovich, S., & Ageno, W. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1823218 · Cited by 22
Shen, T., Shi, J., Wang, N., Yu, X., Zhang, C., Li, J., Wei, L., Ma, C., Zhao, X., Lian, M., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00004.2015 · Cited by 21
Clinical management of rivaroxaban-treated patients
Palareti, G., Ageno, W., Ferrari, A., Filippi, A., Imberti, D., Pengo, V., Rubboli, A., & Toni, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.773310 · Cited by 21
“Route of administration Oral Chemical structure Nonbasic molecule, molecular weight 436 g/mol Pivotal trial(s) i) Prevention of VTE in patients undergoing elective hip or knee replacement surgery [53-56].”
BackgroundEdoxaban: Pharmacological principles, Preclinical and early-phase Clinical Testing
Partida, R. A., & Giugliano, R. P. (2011) · Future Cardiology · doi:10.2217/fca.11.28 · Cited by 22
“com 461 future science group superior to enoxaparin in decreasing the risk of VTE after total hip replacement/total knee replacement, without significant increases in bleeding events [26–29].”
BackgroundRivaroxaban: Practical Considerations for Ensuring Safety and Efficacy
Smythe, M. A., Fanikos, J. R., Gulseth, M. P., Wittkowsky, A. K., Spinler, S. A., Dager, W. E., & Nutescu, E. A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1289 · Cited by 22
Bramlage, P., Turpie, Schmidt, Kreutz, R. H., Lassen, M. R., Jamal, J., & Mantovani, L. G. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s30064 · Cited by 21
Novel Oral Anticoagulants: A Review of New Agents
Wanat, M. A. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2683 · Cited by 25
McDonald, H., Diamantopoulos, A., Wells, P. S., Lees, M., Folkerts, K., Forster, F., & Ananthapavan, J. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.684116 · Cited by 22
Use of novel oral anticoagulant agents in venous thromboembolism
Madan, S., Shah, S., Dale, P., Partovi, S., & Parikh, S. A. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2016.11.17 · Cited by 23
“In the “Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty” (RECORD 1) trial patients received either 10 mg of oral rivaroxaban daily after surgery or 40 mg of subcutaneous enoxaparin the evening before surgery (26) .”
MethodOral anticoagulants in the management of venous thromboembolism
Makaryus, J. N., Halperin, J. L., & Lau, J. F. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.73 · Cited by 28
Current Status of New Anticoagulants in the Management of Venous Thromboembolism
Montoya, R. C., & Gajra, A. (2012) · Advances in Hematology · doi:10.1155/2012/856341 · Cited by 22
“001) without a significant difference in the rates of major bleeding or clinically relevant non-major bleeding [19].”
BackgroundMigliorini, F., Maffulli, N., Velaj, E., Bell, A., Kämmer, D., Eschweiler, J., & Hofmann, U. K. (2024) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-024-04071-w · Cited by 20
“These results are also consistent with findings from studies analysing the effect of aspirin after THA [11, 13, 31, 58–71].”
InfluentialLassen, M. R., Haas, S. K., Kreutz, R. H., Mantovani, L. G., Holberg, G., & Turpie, A. G. G. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615607303 · Cited by 23
Self-citationLi, Q., Dai, B., Xu, J., Yao, Y., Song, K., Zhang, H., Chen, D., & Jiang, Q. Y. (2017) · Medicine · doi:10.1097/md.0000000000007604 · Cited by 20
Goh, E. L., Gurung, P., Ma, S., Pilpel, T., Dale, J. H., Kannan, A., & Anand, S. (2020) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151459319897520 · Cited by 28
“Furthermore, several studies have demonstrated that DOACs are associated with lower rates of VTE without increased risk of hemorrhage compared to conventional anticoagulants for lower limb orthopedic surgery.(10-15) However, there is limited evidence regarding the use of DOACs as VTE prophylaxis following surgery for…”
BackgroundResultMuscatelli, S. R., Zheng, H. T., Hughes, R. E., Cowen, M. E., & Hallstrom, B. R. (2021) · The Journal of Arthroplasty · doi:10.1016/j.arth.2021.01.025 · Cited by 21
“Several studies have investigated factor Xa inhibitors as VTE prophylaxis after TJA [19,28 e 30] and have suggested no differences between factor Xa inhibitors and aspirin for VTE rates [7,31 e 33], although we were not able to establish the non-inferiority of aspirin in our study.”
The direct factor Xa inhibitor rivaroxaban
Verma, A. K., & Brighton, T. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02453.x · Cited by 20
Latest drug developments in the field of cardiovascular disease
Stern, C. S., & Lebowitz, J. (2010) · International Journal of Angiology · doi:10.1055/s-0031-1278379 · Cited by 20
“The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) studies (7,8) demonstrated superiority of rivaroxaban to enoxaparin (Lovenox; sanofi-aventis, France).”
BackgroundNovel anticoagulants and the future of anticoagulation
Garcia, D. A. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70144-6 · Cited by 23
“RECORD1 [1] THA 4,541 40mg SC once daily, beginning the evening prior to surgery 2.”
BackgroundResultSARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition
Erickson, R. I., Huang, C., Allen, C., Ireland, J., Roth, G., Zou, Z., Lu, J., Lafont, B. A. P., Garza, N. L., Brumbaugh, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42140-6 · Cited by 20
Implications of new anticoagulants in primary practice
Perez, A., Eraso, L. H., & Merli, G. J. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12023 · Cited by 21
Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban
Sattari, M., & Lowenthal, D. T. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181da0773 · Cited by 19
Abdulsattar, Y., Bhambri, R., & Nogid, A. (2009) · PubMed Central · Cited by 26
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.